Model: Primary hippocampal neurons from non-transgenic C57BL/6 (nTg) and triple-transgenic 3xTg-AD mice; age groups: young (2–6 mo), middle (8–11 mo), and old (17–28 mo).
Dosage: Nicotinamide 2 mM + EGCG 2 µM applied to cultured neurons for 16 h (in vitro).

Study shows that brief nicotinamide + EGCG treatment restores neuronal energy in 16–24 hours, restores autophagy, reduces amyloid-beta buildup, and boosts neuron survival by ~22% in aging/Alzheimer’s lab models.

Brain &amp; Neurons

Model: C57BL/6J mice, J20 mice, and 3xTg mice 
Dosage: 4.3 μEq l−1 of lithium in drinking water starting at 10 to 12 months of age and continued for 10 to 14 months during aging

Harvard Study: A Low Dose of Lithium May Preserve Cognitive Resilience with Age

Researchers uncover significantly lower brain lithium levels in Alzheimer’s disease patients, and supplementing with a low-dose lithium salt restores memory in an Alzheimer’s disease mouse model.

(The study’s principal investigator, Bruce Yankner [center], with four laboratory employees | The Boston Globe)

A Harvard study suggests lower levels of lithium in the brains of patients with Alzheimer’s disease and that lithium supplementation may help preserve cognitive resilience.

Model: Ten-month-old male EFAD mice 
Dosage: 14.4 ppm of alfatradiol in diet for five months

USC Study: Longevity-Promoting Drug Counteracts a Genetic Predisposition to Alzheimer's

The drug alfatradiol, also known as 17ɑ-estradiol, reduces cognitive errors on a test of memory and lowers neuronal plaques in mice genetically predisposed to Alzheimer’s disease.

(The University of Southern California | College Matchpoint)

Researchers unveil data suggesting the drug alfatradiol improves signs of frailty, reduces cognitive errors, and reduces neuronal plaques in mice with a genetic predisposition to Alzheimer’s disease.

Model: UM-HET3 mice and 5XFAD mice 
Dosage: UM=HET3 mice received 180 mg/kg canagliflozin in chow starting at seven months of age, and FXFAD mice received 180 mg/kg canagliflozin in chow beginning at three months of age

New Study: Diabetes Medication Improves Cognition and Alleviates Alzheimer’s Progression

The diabetes drug canagliflozin improves learning and memory in middle-aged male mice and reduces brain plaques in Alzheimer’s model mice.

The FDA-approved diabetes medication canagliflozin improves cognition in a mouse model of Alzheimer’s disease in males only.

Supplementing with 20 grams of creatine improves the cognition of individuals with Alzheimer’s disease. 

Search Result: Amyloid

Nicotinamide + Ergothioneine Reboot Autophagy and Ease Hallmarks of Brain Aging

Harvard Study: A Low Dose of Lithium May Preserve Cognitive Resilience with Age

USC Study Suggests Longevity-Promoting Drug Counteracts a Genetic Predisposition to Alzheimer’s

Diabetes Medication Improves Cognition and Alleviates Alzheimer’s Progression, Suggests New Study

Creatine Supplement Improves Memory in People with Alzheimer’s: New Pilot Study